tbuckley/cabot-search huggingface dataset:
Pathological Fracture and Prognosis of High-Grade Osteosarcoma of the Extremities: An Analysis of 2,847 Consecutive Cooperative Osteosarcoma Study Group (COSS) Patients
Authors: Lisa Marie Kelley, Miriam Schlegel, Stefanie Hecker-Nolting, Matthias Kevric, Bernhard Haller, Claudia Rössig, Peter Reichardt, Leo Kager, Thomas Kühne, Georg Gosheger, Reinhard Windhager, Katja Specht, Hans Rechl, Per-Ulf Tunn, Daniel Baumhoer, Thomas Wirth, Mathias Werner, Thekla von Kalle, Michaela Nathrath, Stefan Burdach, Stefan Bielack, Irene von Lüttichau
Journal: Journal of Clinical Oncology (2020)

The objective of this study was to investigate potential correlations between pathologic fractures (PFs) and prognosis of patients with primary central high-grade osteosarcoma of the extremities.We retrospectively analyzed 2,847 patients registered in the Consecutive Cooperative Osteosarcoma Study Group database with primary central high-grade osteosarcoma of the extremities, treated between 1980 and 2010. Intended treatment included pre- and postoperative chemotherapy and surgery. Univariable and multivariable survival analyses were performed for all patients and then differentiated for adult and pediatric (≤ 18 years at time of diagnosis) patients.A total of 2,193 patients were ≤ 18 years of age; 11.3% of all patients had PFs. In the overall cohort, presence of PF correlated significantly with tumor site, histologic subtype, relative tumor size, and primary metastases, but not with body mass index or local surgical remission. In univariable analysis, 5-year overall survival (OAS) of patients with and without PF was 63% versus 71%, respectively (P = .007), and 5-year event-free survival (EFS) was 51% versus 58% (P = .026). In pediatric patients, OAS and EFS did not differ significantly between patients with and without PF. In adults, 5-year OAS in patients with and without PF was 46% versus 69% (P < .001), and 5-year EFS was 36% versus 56% (P < .001). In multivariable analysis, PF was not a statistically significant factor for OAS or EFS in the total cohort or in pediatric patients. In adult patients, PF remained an independent prognostic factor for OAS (P = .013; hazard ratio [HR], 1.893). It was not a significant prognostic factor for EFS (P = .263; HR, 1.312).In this largest study to date with extremity osteosarcomas, we observed the occurrence of PF to correlate with inferior OAS expectancies in adult but not in pediatric patients.
Does OPTINAB strategy ("stop-and-go") work in treatment of advanced pancreatic cancer (APC) with nab-paclitaxel (nab) - gemcitabine (gem)?
Authors: Wasif M. Saif, Valerie Relias, Sanjay Hegde, Douglas W Hackenyos, Lisa Ralph, Antonia Maloney, Melissa H Smith, Martin D. Goodman
Journal: Journal of Clinical Oncology (2016)

e15672 Background: MPACT study showed survival benefit of nab-gem vs. gem in APC [Von Hoff D, NEJM 2013]. Sensory peripheral neuropathy is a dose-limiting toxicity associated with nab. Neuromodulatory agents have shown limited activity in ameliorating neuropathy. OPTIMOX (“Stop and Go”) approach offers a reasonable strategy to reduce oxaliplatin-associated neuropathy in pts with colorectal cancer (CRC) [ Tournigand C, JCO 2006]. However no data exists to support an OPTIMOX-like strategy for nab in APC. We present here the first study that describes this approach in managing nab-related neuropathy. Methods: We conducted a retrospective study of pts treated with nab-gem at our cancer center. We collected data by reviewing medical records of those pts who received nab-gem until development of grade 3 neuropathy, then continued gem alone as maintenance therapy; nab was reintroduced in these pts after progression (radiological or increase in CA19-9 > 50%) as long as neuropathy had resolved to < grade 1. We named this “Stop and Go” approach as
Small-sized gadolinium oxide based nanoparticles for high-efficiency theranostics of orthotopic glioblastoma
Authors: Zheyu Shen, Ting Liu, Zhen Yang, Zijian Zhou, Wei Tang, Wenpei Fan, Yijing Liu, Jing Mu, Ling Li, Vladimir I. Bregadze, Swadhin K. Mandal, Anna A. Druzina, Zhenni Wei, Xiaozhong Qiu, Aiguo Wu, Xiaoyuan Chen
Journal: Biomaterials (2020)
CBDCA + Pemetrexed + Bevacizumab and its Maintenance Chemotherapy as a Second Line in a Case of Sole Breast Metastasis from Lung Adenocarcinoma after Complete Response by Gefitinib as a First-Line Chemotherapy
Authors: K. Sato, M. Yoshihara, Y. Takeyama, N. Yogo, M. Ohdate, Y. Fukui, H. Gonda, R. Suzuki
Journal: Annals of Oncology (2012)
Correlation of C609T Polymorphism of NADPH Quinone Oxidoreductase 1 and Clinical Outcome in Amrubicin-Treated Lung Cancer Patients
Authors: M. Nagata, T. Kimura, T. Suzumura, T. Nakai, K. Umekawa, H. Tanaka, K. Matsuura, S. Mitsuoka, N. Yoshimura, S. Kudoh, K. Hirata
Journal: Annals of Oncology (2012)
Specific serology for emerging human coronaviruses by protein microarray
Authors: C Reusken, H Mou, G J Godeke, L van der Hoek, B Meyer, M A Müller, B Haagmans, R de Sousa, N Schuurman, U Dittmer, P Rottier, A Osterhaus, C Drosten, B J Bosch, M Koopmans
Journal: Eurosurveillance (2013)

We present a serological assay for the specific detection of IgM and IgG antibodies against the emerging human coronavirus hCoV-EMC and the SARS-CoV based on protein microarray technology. The assay uses the S1 receptor-binding subunit of the spike protein of hCoV-EMC and SARS-CoV as antigens. The assay has been validated extensively using putative cross-reacting sera of patient cohorts exposed to the four common hCoVs and sera from convalescent patients infected with hCoV-EMC or SARS-CoV.
A Pilot Study Correlating IDH-1/2 Gene Status with 2-Hydroxyglutarate (2HG) Concentration in Plasma and Urine from Patients (PTS) with Glioma
Authors: G. Lombardi, G. Corona, P. Farina, F. Zustovich, R. Bertorelle, P. Fiduccia, A. lla De Puppa, M.P. Gardiman, A. Salvalaggio, G. Toffoli, V. Zagonel
Journal: Annals of Oncology (2012)
High Co-Expression of Cd135 and Cd117 Predicts Poor Outcome in Acute Myeloid Leukemia: A Prospective Study
Authors: S.K. Sharawat, R. Gupta, V. Sreenivas, V. Raina, L. Kumar, A. Sharma, R. Bakhshi, S. Iqbal, S. Bakhshi
Journal: Annals of Oncology (2012)
正確な造血幹細胞回転数は,限界希釈法を用いた移植アッセイにおいてシングルヒットポワソンモデルの代わりに多細胞ポアソンモデルに適合することにより推定される | 文献情報 | J-GLOBAL 科学技術総合リンクセンター
Authors: Bonnefoix Thierry, Callanan Mary
Journal: Blood (2010)
Proteomic Analysis of CSF from Patients with Leptomeningeal Melanoma Metastases Identifies Signatures Associated with Disease Progression and Therapeutic Resistance
Authors: Inna Smalley, Vincent Law, Clayton Wyatt, Brittany Evernden, Bin Fang, John M. Koomen, Eric A. Welsh, Robert J.B. Macaulay, Peter A. Forsyth, Keiran S.M. Smalley
Journal: Clinical Cancer Research (2020)

The development of leptomeningeal melanoma metastases (LMM) is a rare and devastating complication of the late-stage disease, for which no effective treatments exist. Here, we performed a multi-omics analysis of the cerebrospinal fluid (CSF) from patients with LMM to determine how the leptomeningeal microenvironment shapes the biology and therapeutic responses of melanoma cells.
Efficacy of Fexofenadine in Preventing Tyrosine Kinase Inhibitor (TKI)-Induced Interstitial Lung Disease
Authors: R. Ko, S. Sasaki, Y. Namba, A. Ishimori, M. Yoshioka, Y. Yoshioka, S. Tominaga, K. Takahashi
Journal: Annals of Oncology (2012)
Infectious morbidity of breastfed, HIV-exposed uninfected infants under conditions of universal antiretroviral therapy in South Africa: a prospective cohort study
Authors: Stanzi M le Roux, Elaine J Abrams, Kirsten A Donald, Kirsty Brittain, Tamsin K Phillips, Allison Zerbe, David M le Roux, Max Kroon, Landon Myer
Journal: The Lancet Child & Adolescent Health (2020)
Abstract 15036: Personalized Treatment for Heart Failure With Preserved Ejection Fraction Using Deep Reinforcement Learning
Authors: Hui Ren, Sijia Yu, Xiang Li, Wei Qiu, Aoxiao Zhong, Ning Guo, Quanzheng Li
Journal: Circulation (2019)

Background: While a variety of ongoing and upcoming clinical trials targeted at HFpEF population or a subpopulation, clinicians remain struggling when facing the heterogeneous syndrome due to lack ...
Pioneer: A Prospective Molecular Epidemiological Study of EGFR Mutations in Asian Patients (Patients) with Advanced Lung Adenocarcinoma (ADC)
Authors: J.S.-K. Au, S. Yuankai, S. Thongprasert, S. Srinivasan, C.-M. Tsai, M.T. Khoa, K. Heeroma, Y. Itoh, G. Cornelio, P.-C. Yang
Journal: Annals of Oncology (2012)
P-0037 Gastric Signet Ring Cell Carcinoma In a Moroccan Medical Oncology Unit
Authors: Nezar Bouyahia, Khaoula Daoudi, Sami Aziz Brahmi, Hafida Benhammane, Karima Oualla, Fatima Zahra El M'Rabet, Samia Arifi, Nawfel Mellas, Omar El Mesbahi
Journal: Annals of Oncology (2012)
Phase 1 Study of the Selective Akt Inhibitor MK-2206 in Japanese Patients with Advanced Solid Tumors
Authors: Y. Tanabe, T. Doi, K. Tamura, K. Yonemori, M. Kodaira, N. Fuse, H. Bando, Y. Maeda, T. Shimamoto, A. Ohtsu
Journal: Annals of Oncology (2012)
Reproducible Genetic Risk Loci for Anxiety: Results From ∼200,000 Participants in the Million Veteran Program
Authors: Daniel F. Levey, Joel Gelernter, Renato Polimanti, Hang Zhou, Zhongshan Cheng, Mihaela Aslan, Rachel Quaden, John Concato, Krishnan Radhakrishnan, Julien Bryois, Patrick F. Sullivan, Murray B. Stein
Journal: American Journal of Psychiatry (2020)

Anxiety disorders are common and often disabling. The goal of this study was to examine the genetic architecture of anxiety disorders and anxiety symptoms, which are also frequently comorbid with other mental disorders, such as major depressive disorder.
Phase III Trial Evaluating the Addition of Bevacizumab to Endocrine Therapy as First-Line Treatment for Advanced Breast Cancer: The GEICAM/GBG Lea Study. Safety Analysis
Authors: S. Loibl, J.R. La De Haba, G. von Minckwitz, S. Morales, C. Crespo, A. Antón, E. Carrasco, B. Aktas, K. Mehta, M. Martin
Journal: Annals of Oncology (2012)
Pharmacogenetic Predictors of Severe Chronic Peripheral Neuropathy in Stage II-III Colon Cancer (CC) Patients Treated with Oxaliplatin-Based Adjuvant Chemotherapy (CT). A Gemcad Study
Authors: A. Custodio, J. Moreno, J. Aparicio, J. Gallego Plazas, C. Fernández Martos, J. Maurel, D. Ramos, P. Cejas, R. Madero, J. Feliu
Journal: Annals of Oncology (2012)
EZH2 Expression in Colorectal (CRC) Cancer: Single Nucleotide Polymorphism (SNP) Characterization and Correlation With Clinico-Pathological and Molecular Parameters
Authors: L. Fornaro, F. Crea, P. Faviana, G. Masi, C. Vivaldi, V. De Gregorio, E. Paolicchi, G. Fontanini, R. Danesi, A. Falcone
Journal: Annals of Oncology (2012)
Relationship between Progression-Free (PFS) and Overall Survival (OS) in I-Line Randomized Clinical Trials (RCT) for Advanced Renal Cell Carcinoma (RCC): Correlation and Power Analysis
Authors: E. Bria, F. Massari, F. Maines, M. Bonomi, C. Porta, S. Bracarda, F. Cognetti, D. Giannarelli, G. Tortora, M. Milella
Journal: Annals of Oncology (2012)
Chronic allergen exposure drives accumulation of long-lived IgE plasma cells in the bone marrow, giving rise to serological memory
Authors: Seblewongel Asrat, Navneet Kaur, Xia Liu, Li-Hong Ben, Daisuke Kajimura, Andrew J. Murphy, Matthew A. Sleeman, Andre Limnander, Jamie M. Orengo
Journal: Science Immunology (2020)

Immunoglobulin E (IgE) plays an important role in allergic diseases. Nevertheless, the source of IgE serological memory remains controversial. We reexamined the mechanism of serological memory in allergy using a dual reporter system to track IgE+ plasma cells in mice. Short-term allergen exposure resulted in the generation of IgE+ plasma cells that resided mainly in secondary lymphoid organs and produced IgE that was unable to degranulate mast cells. In contrast, chronic allergen exposure led to the generation of long-lived IgE+ plasma cells that were primarily derived from sequential class switching of IgG1, accumulated in the bone marrow, and produced IgE capable of inducing anaphylaxis. IgE+ plasma cells were found in the bone marrow of human allergic, but not nonallergic donors, and allergen-specific IgE produced by these cells was able to induce mast cell degranulation when transferred to mice. These data demonstrate that long-lived IgE+ bone marrow plasma cells arise during chronic allergen exposure and establish serological memory in both mice and humans.
M6A-mediated upregulation of LINC00958 increases lipogenesis and acts as a nanotherapeutic target in hepatocellular carcinoma
Authors: Xueliang Zuo, Zhiqiang Chen, Wen Gao, Yao Zhang, Jinguo Wang, Junfeng Wang, Ming Cao, Juan Cai, Jindao Wu, Xuehao Wang
Journal: Journal of Hematology & Oncology (2020)

Long non-coding RNAs (lncRNAs) possess significant regulatory functions in multiple biological and pathological processes, especially in cancer. Dysregulated lncRNAs in hepatocellular carcinoma (HCC) and their therapeutic applications remain unclear.Differentially expressed lncRNA profile in HCC was constructed using TCGA data. LINC00958 expression level was examined in HCC cell lines and tissues. Univariate and multivariate analyses were performed to demonstrate the prognostic value of LINC00958. Loss-of-function and gain-of-function experiments were used to assess the effects of LINC00958 on cell proliferation, motility, and lipogenesis. Patient-derived xenograft model was established for in vivo experiments. RNA immunoprecipitation, dual luciferase reporter, biotin-labeled miRNA pull-down, fluorescence in situ hybridization, and RNA sequencing assays were performed to elucidate the underlying molecular mechanisms. We developed a PLGA-based nanoplatform encapsulating LINC00958 siRNA and evaluated its superiority for systemic administration.We identified a lipogenesis-related lncRNA, LINC00958, whose expression was upregulated in HCC cell lines and tissues. High LINC00958 level independently predicted poor overall survival. Functional assays showed that LINC00958 aggravated HCC malignant phenotypes in vitro and in vivo. Mechanistically, LINC00958 sponged miR-3619-5p to upregulate hepatoma-derived growth factor (HDGF) expression, thereby facilitating HCC lipogenesis and progression. METTL3-mediated N6-methyladenosine modification led to LINC00958 upregulation through stabilizing its RNA transcript. A PLGA-based nanoplatform loaded with si-LINC00958 was developed for HCC systemic administration. This novel drug delivery system was controlled release, tumor targeting, safe, and presented satisfactory antitumor efficacy.Our results delineate the clinical significance of LINC00958 in HCC and the regulatory mechanisms involved in HCC lipogenesis and progression, providing a novel prognostic indicator and promising nanotherapeutic target.
A Phase 1 Study of EMD 525797 (DI17E6), A Humanized Monoclonal Antibody to Human AV Integrins, in CRPC with Bone Metastases After Chemotherapy
Authors: H. Lannert, A. Heidenreich, J. Gschwend, T. Gil, S. Zastrow, M. Laniado, M. Zühlsdorf, J. Gerloff, W. Uhl, M. Wirth
Journal: Annals of Oncology (2012)
Difelikefalin for the Treatment of Uremic Pruritus
Authors: David J.R. Steele
Journal: New England Journal of Medicine (2020)

The care of patients with end-stage kidney disease is complicated; patients and clinicians alike feel frustration because of our limited options for controlling many of the symptoms associated with this condition. In this context, a phase 3 trial of the drug difelikefalin to treat uremic pruritus in patients undergoing dialysis, the results of which are reported by Fishbane et al.1 in this issue of the Journal, merits commentary. There are both uremic and nonuremic causes of itching in patients undergoing dialysis. Uremic pruritus is associated with depression and other adverse outcomes. The pathophysiology of uremic pruritus is not certain but . . .
A Multi-Center Phase II Clinical Trial of the Chimeric Anti-Mesothelin Monoclonal Antibody Amatuximab in Combination with Chemotherapy for Frontline Therapy of Malignant Pleural Mesothelioma: Updated Clinical Outcomes and Correlative Studies
Authors: M. Reck, R. Hassan, T. Jahan, H.L. Kindler, L. Bazhenova, P. Fatato, J.W. Heyburn, J. Parno, J.D. Maltzman, B. Wallin
Journal: Annals of Oncology (2012)
Final Results of Australasian Gastro-Intestinal Trials Group (AGITG) Arctic Study: AN International Audit of Raltitrexed for Patients with Cardiac Toxicity Induced by Fluoropyrimidines (FP)
Authors: T. Price, K. Wilson, R.J. Simes, D. Yip, C.S. Karapetis, N.C. Tebbutt, V. Gebski, M. Fournier, D.R. Ferry, D. Ransom
Journal: Annals of Oncology (2012)
Prospective Feasibility Study of Cisplatin-Based Chemotherapy with a Short-Term Small Amount of Hydration Method in Advanced Lung Cancer
Authors: A. Hisamoto, E. Ichihara, K. Kudo, K. Uchida, K. Yanase, H. Tanaka, Y. Kato, M. Mizuta, H. Kashihara, U. Fujii, K. Hotta, N. Takigawa, M. Tabata, K. Kiura
Journal: Annals of Oncology (2012)
Prognostic Stratification of Advanced Urothelial Carcinoma (UC) Receiving Second-Line Systemic Therapy Including Time from Prior Chemotherapy (TFPC) as a Prognostic Factor
Authors: G. Sonpavde, G.R. Pond, T.K. Choueiri, R. Fougeray, G. Niegisch, Y. Wong, S.S. Sridhar, W.M. Stadler, C.N. Sternberg, J. Bellmunt
Journal: Annals of Oncology (2012)
True candour about mistakes means full disclosure of system failures
Authors: Rajaratnam Jeyarajah
Journal: BMJ (2020)

I agree with Maskell that we should be honest and volunteer all information to people harmed by provision of services.1 But why should we stop at doctors’ honesty about mishaps during patient care? Why shouldn’t we make the public aware of the shortages nearly all hospitals face and the stress and unrealistic demands this places on staff?

I …
Influenza-induced monocyte-derived alveolar macrophages confer prolonged antibacterial protection
Authors: Helena Aegerter, Justina Kulikauskaite, Stefania Crotta, Harshil Patel, Gavin Kelly, Edith M. Hessel, Matthias Mack, Soren Beinke, Andreas Wack
Journal: Nature Immunology (2020)
The art of innovation: clinical development of trastuzumab deruxtecan and redefining how antibody-drug conjugates target HER2-positive cancers
Authors: A. Yver, T. Agatsuma, J.-C. Soria
Journal: Annals of Oncology (2020)

Antibody-drug conjugates (ADCs) first entered clinical development in the 1980s, and >80 ADCs have been evaluated in the clinic, yet only five have achieved regulatory approval.1–3 The efficacy of early, murine-based ADCs did not exceed that of traditional chemotherapy; furthermore, unstable linkers resulted in systemic exposure to the payload and unacceptable toxicity.1 At Daiichi Sankyo Co., Ltd (DS), an ADC research team led by Toshinori Agatsuma and Yuki Abe established in 2010 at Shinagawa R&D Center, Tokyo, Japan set out to rationally design a technologically advanced, unique, and effective ADC technology.
Autologous Stem Cell Transplantation (HCT) with or Without Total Body Irradiation (TBI) in Newly Diagnosed Mantle Cell Lymphoma (MCL) Patients
Authors: M. Szymczyk, J. Romejko-Jarosinska, B. Brzeska, W. Osiadacz, K. Domanska-Czyz, M. Smorczewska, O. Hermine, M.H. Dreyling, J.A. Walewski
Journal: Annals of Oncology (2012)
Rules suspending doctors’ pension benefits in cases of crime are “inherently unfair,” says judge
Authors: Clare Dyer
Journal: BMJ (2020)

Rules allowing NHS pension benefits to be suspended if a doctor is charged with a serious crime are unlawful, unfair, and breach the presumption of innocence, a High Court judge has ruled.1

The judgment is a victory for the BMA and an embarrassment for health and social care secretary Matt Hancock, who introduced the rules in April 2019. The judge, Mrs Justice Andrews, said, “There is no evidence that anyone, from the minister himself downwards, turned their mind to the presumption of innocence and how this new power might impact upon it, at any stage before …
Reassessment Intervals for Transition From Low to High Fracture Risk Among Adults Older Than 50 Years
Authors: William D. Leslie, Suzanne N. Morin, Lisa M. Lix, Patrick Martineau, Mark Bryanton, Eugene V. McCloskey, Helena Johansson, Nicholas C. Harvey, John A. Kanis
Journal: JAMA Network Open (2020)

<h3>Importance</h3> Fracture risk scores are used to identify individuals at high risk of major osteoporotic fracture or hip fracture for antiosteoporosis treatment. For those not meeting treatment thresholds at baseline, the optimal interval for reassessing fracture risk is uncertain. <h3>Objective</h3> To examine reassessment intervals for transition from low to high fracture risk under guidelines-defined treatment thresholds. <h3>Design, Setting, and Participants</h3> This retrospective cohort study included persons aged 50 years or older with fracture risk below treatment thresholds at baseline who had fracture risk reassessed at least 1 year later. Data were obtained from a population-based bone mineral density registry (baseline assessment during 1996-2015; reassessment to 2016) in the Province of Manitoba, Canada. Primary analysis was performed from May to June 2019. Analysis for the revision was performed in October 2019. <h3>Main Outcomes and Measures</h3> The primary outcome was time to transition from low (below the treatment threshold) to high fracture risk (treatment-qualifying risk score using osteoporosis clinical practice guidelines strategies for Canada, the United States, and the United Kingdom). <h3>Results</h3> The study population consisted of 10 564 individuals (94.1% women; mean [SD] age at baseline, 63.2 [8.2] years). At the time of reassessment (a mean [SD] interval of 5.2 [2.9] years between initial and subsequent fracture risk assessment), 690 (6.6%) had reached the fixed major osteoporotic fracture treatment threshold of 20%, 1546 (16.2%) had reached the fixed hip treatment threshold of 3%, and 932 (9.4%) had reached the age-dependent major osteoporotic fracture treatment threshold. Among those below 25% of the treatment threshold at baseline for each guideline, few (0%-3.0%) reached guidelines-defined high fracture risk at follow-up. In contrast, among those at the upper end of the scale for each guideline (75%-99% of the treatment threshold at baseline), 30.6% to 74.4% reached guidelines-defined high fracture risk. An increased number of clinical risk factors was associated with increased likelihood of reaching guidelines-defined high fracture risk (range for 3 guidelines, 17.1%-28.2%) compared with unchanged or decreased clinical risk factors (range for 3 guidelines, 3.3%-12.8%) (<i>P</i> &lt; .001). Estimated time for 10% of the population to reach treatment-qualifying high fracture risk ranged from fewer than 3 years to more than 15 years. <h3>Conclusions and Relevance</h3> The findings suggest that baseline fracture risk (as a fraction of the treatment threshold) and change in clinical risk factors can identify individuals with low and high probability of guidelines-defined high fracture risk during follow-up, thereby potentially helping to inform the reassessment interval.